Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05415410 · ClinicalTrials.gov registry record · Phase 2
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
A Phase 2 study, sponsored by VectivBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT05415410 is a Phase 2 study that was terminated before completion, run by VectivBio. The registered enrollment target is 31 participants.
The verdict
NCT05415410, a Phase 2 study, was terminated before completion, sponsored by VectivBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal aGVHD.
Interventions
- DRUG Apraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2024-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05415410
The ClinicalTrials.gov registry entry for NCT05415410 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VectivBio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apraglutide is the first listed.
NCT05415410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05415410 about?
NCT05415410 is a clinical study titled "Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)". The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal aGVHD.
What is the current status of trial NCT05415410?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2022-05-25. Estimated completion is 2024-12-17.
What interventions are being tested in trial NCT05415410?
The interventions under investigation include: Apraglutide (DRUG).
Who is sponsoring clinical trial NCT05415410?
This trial is sponsored by VectivBio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.